Seed et al. explore a cohort of PARPi-treated advanced prostate cancers, studying plasma cell-free DNA samples for genomic alterations that provide drug resistance. They find multiple mutations emerging in parallel over time and show links to clinical outcome, and evidence of how tumors with BRCA2 deletions can survive PARPi blockade.
This randomized clinical trial examines different treatments for patients with unresectable colorectal cancer with liver-only metastases.
Discover the latest advancements in pancreatic cancer vaccines and how they aim to prevent recurrent cancer by targeting specific mutations. Stay informed with current trials…
The cytomorphologic features of thoracic SMARCA4–deficient malignancies are not entirely specific but are distinctive enough to suspect the diagnosis in the appropriate clinical setting. The…
Introducing #ASHinaFlash, your fast track to essential #ASH24 content! Get expert highlights of must-see sessions and quick takes on the latest #hematology b…
During IWWM-12, the Lymphoma Hub was pleased to speak with Gareth Morgan, NYU Grossman School of Medicine, New York, US. We asked, What insights can…
Patterns, an open-access journal, has issued a call for novel data science research that could drive urban sustainability
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
The 2024 SABCS® will explore the hype and reality of AI during two sessions, including a discussion on revolutionizing diagnosis and discovery, moderated by Frederick…
Key PointsLargest and most diverse genetic study of plasma fibrinogen identifies 54 regions (18 novel), housing 69 distinct variants (20 novel).Links to (1
